A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
- Conditions
- HIV Infections
- Registration Number
- NCT00002334
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
- Detailed Description
Patients are randomized to receive a minimum of 80 weeks of AZT alone, AZT plus ddC, AZT plus Ro 31-8959, or all three drugs.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (25)
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
UCD Med Ctr
🇺🇸Sacramento, California, United States
Davies Med Ctr
🇺🇸San Francisco, California, United States
Mount Zion Med Ctr / UCSF
🇺🇸San Francisco, California, United States
Pacific Oaks Med Group
🇺🇸Sherman Oaks, California, United States
Sunnyvale Med Clinic
🇺🇸Sunnyvale, California, United States
Novum Inc
🇺🇸Pittsburgh, Pennsylvania, United States
Howard Univ
🇺🇸Washington, District of Columbia, United States
Miami Veterans Administration Med Ctr
🇺🇸Miami, Florida, United States
Univ of Miami School of Medicine
🇺🇸Miami, Florida, United States
Scroll for more (15 remaining)Phoenix Body Positive🇺🇸Phoenix, Arizona, United States